Security key
90466Y202
Unicycive Therapeutics, Inc. - Common Stock (UNCY)
CUSIP: 90466Y202
Q3 2025 13F Holders as of 30 Sep 2025
- Security type / class
- Equity / Common Stock
- Total 13F shares
- 6,285,927
- Total 13F value
- $27,416,349
- Share change
- +1,141,709
- SEC-reported price per share
- $4.36
- Number of holders
- 30
- Value change
- +$4,969,291
- Number of buys
- 21
- Number of sells
- 4
- Shares outstanding
- 26,667,566
Holder snapshot
6 signals
Security identity
Names, identifiers, and filing context for this profile.
1 source field
Report period
Q3 2025
Institutions
30
Top holders
10
UNCY full security history
Ownership snapshot
Full 13F holder table
Unicycive Therapeutics, Inc. SEC filings
Unicycive Therapeutics, Inc. company facts
Broader feeds
Reporting periods
Holder history for CUSIP 90466Y202
Recent filing periods:
Ownership snapshot
Top reported holders of UNCY - Unicycive Therapeutics, Inc. - Common Stock (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
Vivo Opportunity Fund Hol...
Disclosed value leader
Vivo Opportunity Fund Hol...
Comparable rows
15/15
Latest evidence
30 Sep 2025
13D/G
13F
Lead comparable stake: 10%
13D/G row: Vivo Opportunity Fund Holdings, L.P.
Showing 1-6 of 15 holder rows.
Quick read
Vivo Opportunity Fund Holdings, L.P. leads the comparable SEC ownership view at 10%.
15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens Vivo Opportunity Fund Holdings, L.P.'s linked filing trail.
Comparable ownership
Top 5
Vivo Opportunity Fund Holdings, L.P.
10%
BIOTECHNOLOGY VALUE FUND L P
10%
Nantahala Capital Management, LLC
10%
RA CAPITAL MANAGEMENT, L.P.
9.9%
Walleye Capital LLC
4.8%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| Vivo Opportunity Fund Holdings, L.P. |
13D/G
|
10%
|
$26,579,323
6,096,175 shares
|
$0 | 30 Sep 2025 |
| BIOTECHNOLOGY VALUE FUND L P |
13D/G
BVF PARTNERS L P/IL
|
10%
|
$7,439,864
1,417,117 shares
|
$0 | 30 Jun 2025 |
| Nantahala Capital Management, LLC |
13F
13D/G
Company
|
10%
from 13D/G
|
$4,559,826
939,202 shares
|
— | 30 Jun 2025 |
| RA CAPITAL MANAGEMENT, L.P. |
13D/G
|
9.9%
|
$8,370,042
13,285,781 shares
|
+$1,112,366 | 31 Mar 2025 |
| Walleye Capital LLC |
13D/G
|
4.8%
|
$3,150,000
5,000,000 shares
|
$0 | 31 Dec 2024 |
| GREAT POINT PARTNERS LLC |
13F
13D/G
Company
|
4.5%
from 13D/G
|
$3,799,582
796,558 shares
|
— | 30 Jun 2025 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q3 2025
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
30
Shares
6,285,927
Rows available
30
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q3 2025 vs Q2 2025 Across Filers
Q2 2025 holders
19
Q3 2025 holders
30
Holder diff
11
| Investor | Q2 2025 Shares | Q3 2025 Shares | Share Diff | Share Chg % | Q2 2025 value | Q3 2025 value | Value change | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend